Publication:
Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Final findings from the CONTROL trial

dc.conference.dateMAY 03-05, 2022
dc.conference.titleEuropean-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress
dc.contributor.authorChan, A.
dc.contributor.authorRuiz Borrego, M.
dc.contributor.authorMarx, G.
dc.contributor.authorBrufsky, A.
dc.contributor.authorChien, A. J.
dc.contributor.authorThirlwell, M. P.
dc.contributor.authorTrudeau, M. E.
dc.contributor.authorBose, R.
dc.contributor.authorSaenz, J. A. Garcia
dc.contributor.authorEgle, D.
dc.contributor.authorPistilli, B.
dc.contributor.authorWassermann, J.
dc.contributor.authorCheong, K. A.
dc.contributor.authorSemsek, D.
dc.contributor.authorSinger, C. F.
dc.contributor.authorDiprimeo, D.
dc.contributor.authorForuzan, N.
dc.contributor.authorMcCulloch, L. M.
dc.contributor.authorBarcenas, C. H.
dc.contributor.authoraffiliation[Chan, A.] Breast Canc Res Ctr BCRC WA, Med Oncol, Nedlands, WA, Australia
dc.contributor.authoraffiliation[Ruiz Borrego, M.] Hosp Univ Virgen del Rocio, Oncol, Seville, Spain
dc.contributor.authoraffiliation[Marx, G.] Univ Sydney, Med Oncol, Sydney, NSW, Australia
dc.contributor.authoraffiliation[Brufsky, A.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Oncol, Pittsburgh, PA USA
dc.contributor.authoraffiliation[Chien, A. J.] Univ Calif San Francisco, Med Oncol, San Francisco, CA 94143 USA
dc.contributor.authoraffiliation[Thirlwell, M. P.] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Med Med Oncol Dept, Glen Site, Montreal, PQ, Canada
dc.contributor.authoraffiliation[Trudeau, M. E.] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Med Oncol, Toronto, ON, Canada
dc.contributor.authoraffiliation[Bose, R.] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA
dc.contributor.authoraffiliation[Saenz, J. A. Garcia] Hosp Clin Univ San Carlos, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Egle, D.] Univ Frauenklin Innsbruck, Gynaecol, Innsbruck, Austria
dc.contributor.authoraffiliation[Pistilli, B.] Gustave Roussy Canc Ctr, Breast Canc Grp, Villejuif, France
dc.contributor.authoraffiliation[Wassermann, J.] Hop La Pitie Salpetriere, Med Oncol, Paris, France
dc.contributor.authoraffiliation[Cheong, K. A.] Adelaide Canc Ctr, Med Oncol, Adelaide, SA, Australia
dc.contributor.authoraffiliation[Semsek, D.] Praxis Diakonie Krankenhaus Onkol Schwerpunktprax, Med Oncol, Fribourg, Switzerland
dc.contributor.authoraffiliation[Singer, C. F.] Med Univ Vienna, Med Oncol, Vienna, Austria
dc.contributor.authoraffiliation[Diprimeo, D.] Puma Biotechnol Inc, Biostat, San Francisco, CA USA
dc.contributor.authoraffiliation[Foruzan, N.] Puma Biotechnol Inc, Clin Operat, San Francisco, CA USA
dc.contributor.authoraffiliation[McCulloch, L. M.] Puma Biotechnol Inc, Clin Sci Dept, San Francisco, CA USA
dc.contributor.authoraffiliation[Barcenas, C. H.] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol Dept, Houston, TX 77030 USA
dc.date.accessioned2023-05-03T14:39:56Z
dc.date.available2023-05-03T14:39:56Z
dc.date.issued2022-05-05
dc.identifier.doi10.1016/j.annonc.2022.03.089
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422004689/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21900
dc.identifier.wosID792494100075
dc.issue.number3
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen del Rocío
dc.page.numberS156-S156
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleEffect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Final findings from the CONTROL trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files